You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMinocycline
Accession NumberDB01017  (APRD00547)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem]
Structure
Thumb
Synonyms
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
7-Dimethylamino-6-demethyl-6-deoxytetracycline
Minociclina
Minociclinum
Minocyclin
Minocyclinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ArestinPowder1 mg/1OralOra Pharma, Inc.2011-03-21Not applicableUs
Arestin MicrospheresPowder1 mgOralOrapharma Inc2008-07-27Not applicableCanada
Dom-minocycline CapsulesCapsule50 mgOralDominion Pharmacal2000-11-24Not applicableCanada
Dom-minocycline CapsulesCapsule100 mgOralDominion Pharmacal2000-11-24Not applicableCanada
Enca 100mgCapsule100 mgOralPrempharm Inc2003-10-032009-08-05Canada
Enca 50mgCapsule50 mgOralPrempharm Inc2003-10-032009-08-05Canada
MinocinKitOnset Dermatologics, LLC2013-06-172016-01-31Us
MinocinInjection100 mg/1IntravenousThe Medicines Company2013-04-19Not applicableUs
MinocinCapsule, coated pellets75 mg/1OralOnset Dermatologics LLC1990-05-31Not applicableUs
MinocinCapsule, coated pellets100 mg/1OralAphena Pharma Solutions Tennessee, Llc1990-05-31Not applicableUs
MinocinCapsule, coated pellets50 mg/1OralOnset Dermatologics LLC1990-05-31Not applicableUs
MinocinInjection100 mg/1IntravenousRempex Pharmaceuticals, Inc2013-04-19Not applicableUs
MinocinCapsule100 mgOralGlaxosmithkline Inc1996-10-252012-12-10Canada
MinocinKitOnset Dermatologics, LLC2013-06-172016-01-31Us
MinocinCapsule50 mgOralGlaxosmithkline Inc1996-10-252012-12-10Canada
MinocinCapsule, coated pellets100 mg/1OralOnset Dermatologics LLC1990-05-31Not applicableUs
Minocin Cap 100mgCapsule100 mgOralLederle Cyanamid Canada Inc.1971-12-311997-08-14Canada
Minocin Cap 50mgCapsule50 mgOralLederle Cyanamid Canada Inc.1974-12-311997-08-14Canada
Minocin KitCapsule, coated pellets50 mg/1OralTriax Pharmaceuticals, LLC2007-09-012016-01-31Us
Minocin KitCapsule, coated pellets100 mg/1OralTriax Pharmaceuticals, LLC2007-09-012016-01-31Us
MinocyclineCapsule100 mgOralIvax Pharmaceuticals Incorporated2000-01-24Not applicableCanada
MinocyclineCapsule50 mgOralSanis Health Inc2010-02-25Not applicableCanada
MinocyclineCapsule100 mgOralSanis Health Inc2010-02-25Not applicableCanada
Minocycline-100Capsule100 mgOralPro Doc Limitee1995-12-31Not applicableCanada
Minocycline-50Capsule50 mgOralPro Doc Limitee1995-12-31Not applicableCanada
Mylan-minocyclineCapsule100 mgOralMylan Pharmaceuticals Ulc1997-02-21Not applicableCanada
Mylan-minocyclineCapsule50 mgOralMylan Pharmaceuticals Ulc1997-02-21Not applicableCanada
Nu-minocyclineCapsule50 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-minocyclineCapsule100 mgOralNu Pharm IncNot applicableNot applicableCanada
PHL-minocyclineCapsule100 mgOralPharmel Inc2009-02-102016-10-25Canada
PHL-minocyclineCapsule50 mgOralPharmel Inc2009-02-102016-10-25Canada
PMS-minocyclineCapsule50 mgOralPharmascience Inc2007-10-01Not applicableCanada
PMS-minocyclineCapsule100 mgOralPharmascience Inc2000-06-12Not applicableCanada
PMS-minocyclineCapsule100 mgOralPharmascience Inc2007-10-01Not applicableCanada
PMS-minocyclineCapsule50 mgOralPharmascience Inc2000-06-12Not applicableCanada
Ran-minocyclineCapsule100 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-minocyclineCapsule50 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ratio-minocyclineCapsule100 mgOralRatiopharm Inc Division Of Teva Canada Limited1993-12-312014-09-19Canada
Ratio-minocyclineCapsule50 mgOralRatiopharm Inc Division Of Teva Canada Limited1993-12-312014-09-19Canada
Riva-minocyclineCapsule100 mgOralLaboratoire Riva Inc2000-05-232013-07-31Canada
Riva-minocycline 50 mgCapsule50 mgOralLaboratoire Riva Inc2000-05-232013-07-31Canada
Sandoz MinocyclineCapsule50 mgOralSandoz Canada Incorporated2000-11-06Not applicableCanada
Sandoz MinocyclineCapsule100 mgOralSandoz Canada Incorporated2000-11-06Not applicableCanada
SolodynTablet, film coated, extended release65 mg/1OralValeant Pharmaceuticals North America LLC2009-07-23Not applicableUs
SolodynTablet, film coated, extended release105 mg/1OralValeant Pharmaceuticals North America LLC2010-09-27Not applicableUs
SolodynTablet, film coated, extended release115 mg/1OralValeant Pharmaceuticals North America LLC2009-07-23Not applicableUs
SolodynTablet, film coated, extended release55 mg/1OralValeant Pharmaceuticals North America LLC2010-09-27Not applicableUs
SolodynTablet, film coated, extended release80 mg/1OralPhysicians Total Care, Inc.2011-07-18Not applicableUs
SolodynTablet, film coated, extended release80 mg/1OralValeant Pharmaceuticals North America LLC2010-09-27Not applicableUs
Teva-minocyclineCapsule100 mgOralTeva Canada Limited1994-12-31Not applicableCanada
Teva-minocyclineCapsule50 mgOralTeva Canada Limited1994-12-31Not applicableCanada
XiminoCapsule, extended release45 mg/1OralRanbaxy Laboratories Inc.2012-09-01Not applicableUs
XiminoCapsule, extended release90 mg/1OralRanbaxy Laboratories Inc.2012-09-01Not applicableUs
XiminoCapsule, extended release135 mg/1OralRanbaxy Laboratories Inc.2012-09-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-minocycline Cap 100mgCapsule100 mgOralApotex Inc1994-12-31Not applicableCanada
Apo-minocycline Cap 50mgCapsule50 mgOralApotex Inc1994-12-31Not applicableCanada
DynacinTablet50 mg/1OralPar Pharmaceutical, Inc.2011-06-20Not applicableUs
DynacinTablet75 mg/1OralPar Pharmaceutical, Inc.2011-06-20Not applicableUs
DynacinTablet100 mg/1OralPar Pharmaceutical, Inc.2011-06-20Not applicableUs
MinocyclineTablet50 mg/1OralPar Pharmaceutical, Inc.2003-04-16Not applicableUs
MinocyclineTablet, film coated75 mg/1OralSun Pharmaceuticals Industries Inc.2016-01-29Not applicableUs
MinocyclineTablet75 mg/1OralPar Pharmaceutical, Inc.2003-04-16Not applicableUs
MinocyclineTablet, film coated100 mg/1OralSun Pharmaceuticals Industries Inc.2016-01-29Not applicableUs
MinocyclineTablet50 mg/1OralAv Kare, Inc.2015-05-08Not applicableUs
MinocyclineTablet100 mg/1OralPar Pharmaceutical, Inc.2003-04-16Not applicableUs
MinocyclineTablet100 mg/1OralAv Kare, Inc.2015-05-08Not applicableUs
MinocyclineTablet, film coated50 mg/1OralSun Pharmaceuticals Industries Inc.2016-01-29Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralA S Medication Solutions1991-12-30Not applicableUs
Minocycline HydrochlorideTablet, extended release135 mg/1OralSandoz Inc2009-08-13Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralREMEDYREPACK INC.2011-03-30Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralPhysicians Total Care, Inc.2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralRanbaxy Pharmaceuticals Inc.2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralDispensing Solution, Inc.1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralSun Pharmaceutical Industries, Inc.2013-05-13Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline HydrochlorideTablet, extended release135 mg/1OralLupin Pharmaceuticals, Inc.2012-02-14Not applicableUs
Minocycline HydrochlorideTablet50 mg/1OralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralTeva Pharmaceuticals USA Inc1992-05-01Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralAidarex Pharmaceuticals LLC2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-08Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralPd Rx Pharmaceuticals, Inc.1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1Oralbryant ranch prepack1999-06-10Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralActavis Pharma, Inc.1999-06-10Not applicableUs
Minocycline HydrochlorideTablet, film coated75 mg/1OralDr. Reddy's Laboratories Limited2008-01-23Not applicableUs
Minocycline HydrochlorideTablet, film coated75 mg/1OralRanbaxy Pharmaceuticals Inc.2004-06-29Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralPreferred Pharmaceuticals, Inc.2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralREMEDYREPACK INC.2015-04-16Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralREMEDYREPACK INC.2016-06-13Not applicableUs
Minocycline HydrochlorideTablet, extended release90 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-032016-11-29Us
Minocycline HydrochlorideTablet, film coated, extended release45 mg/1OralPru Gen Pharmaceuticals2012-11-19Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralNorthwind Pharmaceuticals, LLC2014-08-20Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralDIRECT RX2015-11-30Not applicableUs
Minocycline HydrochlorideTablet, film coated, extended release45 mg/1OralAurobindo Pharma Limited2012-11-19Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralA S Medication Solutions1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralA S Medication Solutions2015-04-02Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralRanbaxy Pharmaceuticals Inc.2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralAmerican Health Packaging2012-09-30Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralSun Pharmaceutical Industries, Inc.2013-05-13Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralA S Medication Solutions1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralUnit Dose Services2008-03-11Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralPhysicians Total Care, Inc.2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralAv Pak2015-01-28Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralPd Rx Pharmaceuticals, Inc.1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralAurobindo Pharma Limited2008-03-11Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralAphena Pharma Solutions Tennessee, Llc1991-12-30Not applicableUs
Minocycline HydrochlorideTablet75 mg/1OralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralTeva Pharmaceuticals USA Inc1992-05-01Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralAidarex Pharmaceuticals LLC2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralActavis Pharma, Inc.1991-12-30Not applicableUs
Minocycline HydrochlorideTablet, film coated100 mg/1OralDr. Reddy's Laboratories Limited2008-01-23Not applicableUs
Minocycline HydrochlorideTablet, film coated100 mg/1OralRanbaxy Pharmaceuticals Inc.2004-06-29Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralAmerican Health Packaging2008-08-272015-12-29Us
Minocycline HydrochlorideCapsule100 mg/1OralDIRECT RX2015-11-30Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralREMEDYREPACK INC.2016-09-08Not applicableUs
Minocycline HydrochlorideTablet, extended release135 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-032016-11-29Us
Minocycline HydrochlorideTablet, film coated, extended release90 mg/1OralPru Gen Pharmaceuticals2012-11-19Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralREMEDYREPACK INC.2013-06-03Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralProficient Rx LP2000-12-22Not applicableUs
Minocycline HydrochlorideTablet, film coated, extended release90 mg/1OralAurobindo Pharma Limited2012-11-19Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralA S Medication Solutions1992-05-01Not applicableUs
Minocycline HydrochlorideTablet, extended release45 mg/1OralSandoz Inc2009-08-13Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralPhysicians Total Care, Inc.2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralRanbaxy Pharmaceuticals Inc.2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralDepartment Of State Health Services, Pharmacy Branch1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-04-02Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralKAISER FOUNDATION HOSPITALS2006-08-04Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralTeva Pharmaceuticals USA Inc2004-06-30Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralAv Pak2014-11-07Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralClinical Solutions Wholesale, Llc2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralAurobindo Pharma Limited2008-03-11Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralA S Medication Solutions1991-12-30Not applicableUs
Minocycline HydrochlorideTablet100 mg/1OralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralActavis Pharma, Inc.1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralCardinal Health1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1Oralbryant ranch prepack2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline HydrochlorideTablet, extended release45 mg/1OralLupin Pharmaceuticals, Inc.2012-02-14Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralPreferred Pharmaceuticals Inc.2016-08-22Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.1999-03-23Not applicableUs
Minocycline HydrochlorideTablet, film coated, extended release135 mg/1OralPru Gen Pharmaceuticals2012-11-19Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralREMEDYREPACK INC.2013-07-08Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralProficient Rx LP2000-12-22Not applicableUs
Minocycline HydrochlorideTablet, film coated, extended release135 mg/1OralAurobindo Pharma Limited2012-11-19Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralSun Pharmaceutical Industries, Inc.2013-05-13Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralA S Medication Solutions2000-12-22Not applicableUs
Minocycline HydrochlorideTablet, extended release90 mg/1OralSandoz Inc2009-08-13Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralLiberty Pharmaceuticals, Inc.2000-12-22Not applicableUs
Minocycline HydrochlorideTablet, film coated50 mg/1OralDr. Reddy's Laboratories Limited2008-01-23Not applicableUs
Minocycline HydrochlorideTablet, film coated50 mg/1OralRanbaxy Pharmaceuticals Inc.2004-06-29Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralCarilion Materials Management1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralAv Kare, Inc.2011-07-26Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralClinical Solutions Wholesale, Llc2015-04-02Not applicableUs
Minocycline HydrochlorideTablet, extended release45 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-02-032016-11-29Us
Minocycline HydrochlorideCapsule50 mg/1OralUnit Dose Services2008-03-11Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralClinical Solutions Wholesale2008-03-11Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralAurobindo Pharma Limited2008-03-11Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralA S Medication Solutions2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralDIRECT RX2014-01-01Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralRebel Distributors Corp.2000-11-30Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralLake Erie Medical DBA Quality Care Products LLC1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralCardinal Health1992-05-01Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1Oralbryant ranch prepack2000-12-22Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralTorrent Pharmaceuticals Limited2015-04-02Not applicableUs
Minocycline HydrochlorideTablet, extended release90 mg/1OralLupin Pharmaceuticals, Inc.2012-02-14Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralDIRECT RX2016-09-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AkneminNot Available
Apo-MinocyclineNot Available
KlinomycinNot Available
MinodermNot Available
MinomycinNot Available
MinopenNot Available
MinoxNot Available
MinozNot Available
VectrinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Minocycline hydrochloride
13614-98-7
Thumb
  • InChI Key: GLMUAFMGXXHGLU-VQAITOIOSA-N
  • Monoisotopic Mass: 493.161578
  • Average Mass: 493.94
DBSALT000721
Categories
UNIIFYY3R43WGO
CAS number10118-90-8
WeightAverage: 457.4764
Monoisotopic: 457.184900233
Chemical FormulaC23H27N3O7
InChI KeyDYKFCLLONBREIL-KVUCHLLUSA-N
InChI
InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
IUPAC Name
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
SMILES
[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Pharmacology
IndicationFor the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis.
Structured Indications
PharmacodynamicsMinocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.
Mechanism of actionMinocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
30S ribosomal protein S9Proteinyes
inhibitor
Escherichia coli (strain K12)P0A7X3 details
30S ribosomal protein S4Proteinyes
inhibitor
Escherichia coli (strain K12)P0A7V8 details
16S rRNANucleotideunknown
inhibitor
Enteric bacteria and other eubacterianot applicabledetails
Interleukin-1 betaProteinunknown
modulator
HumanP01584 details
Arachidonate 5-lipoxygenaseProteinunknown
inhibitor
HumanP09917 details
Matrix metalloproteinase-9Proteinunknown
inhibitor
HumanP14780 details
Vascular endothelial growth factor AProteinunknown
inhibitor
HumanP15692 details
Caspase-1Proteinunknown
negative modulator
HumanP29466 details
Caspase-3Proteinunknown
negative modulator
HumanP42574 details
Cytochrome cProteinunknown
negative modulator
HumanP99999 details
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.
Volume of distributionNot Available
Protein binding55% to 76%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life11-22 hours
ClearanceNot Available
ToxicityMinocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD50=2380 mg/kg (rat, oral), LD50=3600 mg/kg (mouse, oral)
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategorySMPDB ID
Minocycline Action PathwayDrug actionSMP00292
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneMinocycline may increase the central nervous system depressant (CNS depressant) activities of 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcenocoumarolMinocycline may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AcitretinThe risk or severity of adverse effects can be increased when Minocycline is combined with Acitretin.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Minocycline is combined with Adapalene.Approved
adipiplonMinocycline may increase the central nervous system depressant (CNS depressant) activities of adipiplon.Investigational
AgomelatineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlfaxaloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlitretinoinThe risk or severity of adverse effects can be increased when Minocycline is combined with Alitretinoin.Approved, Investigational
AlphacetylmethadolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlprazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmdinocillinThe therapeutic efficacy of Amdinocillin can be decreased when used in combination with Minocycline.Withdrawn
AmisulprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmoxicillinThe therapeutic efficacy of Amoxicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
AmperozideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmpicillinThe therapeutic efficacy of Ampicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
AripiprazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArticaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Minocycline.Approved, Investigational
Atracurium besylateMinocycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Vet Approved
AzelastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzidocillinThe therapeutic efficacy of Azidocillin can be decreased when used in combination with Minocycline.Approved
AzlocillinThe therapeutic efficacy of Azlocillin can be decreased when used in combination with Minocycline.Approved
BacampicillinThe therapeutic efficacy of Bacampicillin can be decreased when used in combination with Minocycline.Approved
BaclofenMinocycline may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Minocycline.Investigational
BenperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
Benzathine benzylpenicillinThe therapeutic efficacy of Benzathine benzylpenicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
BenzocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
Benzyl alcoholMinocycline may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BenzylpenicillinThe therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
Benzylpenicillin PotassiumThe therapeutic efficacy of Benzylpenicillin Potassium can be decreased when used in combination with Minocycline.Approved
Benzylpenicilloyl PolylysineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Minocycline.Approved
BexaroteneThe risk or severity of adverse effects can be increased when Minocycline is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Minocycline can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth SubsalicylateThe serum concentration of Minocycline can be decreased when it is combined with Bismuth Subsalicylate.Approved, Vet Approved
BrexpiprazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BrompheniramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Withdrawn
BupivacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CalciumThe serum concentration of Minocycline can be decreased when it is combined with Calcium.Nutraceutical
Calcium AcetateThe serum concentration of Minocycline can be decreased when it is combined with Calcium Acetate.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideThe serum concentration of Minocycline can be decreased when it is combined with Calcium Chloride.Approved
Calcium citrateThe serum concentration of Minocycline can be decreased when it is combined with Calcium citrate.Approved
Calcium glubionateThe serum concentration of Minocycline can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Minocycline can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Minocycline can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
CarbamazepineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbenicillinThe therapeutic efficacy of Carbenicillin can be decreased when used in combination with Minocycline.Approved
CarbinoxamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Vet Approved
CarindacillinThe therapeutic efficacy of Carindacillin can be decreased when used in combination with Minocycline.Approved
CarisoprodolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CetirizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Withdrawn
ChloroprocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChlorphenamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorpromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinchocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
Cisatracurium besylateMinocycline may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
ClemastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClidiniumMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
clomethiazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClorazepateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
CloxacillinThe therapeutic efficacy of Cloxacillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
ClozapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CyclacillinThe therapeutic efficacy of Cyclacillin can be decreased when used in combination with Minocycline.Approved
CyclizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyproheptadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapiprazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DecamethoniumMinocycline may increase the neuromuscular blocking activities of Decamethonium.Approved
deramciclaneMinocycline may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Investigational
DesfluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DetomidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromoramideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved
DiazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DicloxacillinThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
DicoumarolMinocycline may increase the anticoagulant activities of Dicoumarol.Approved
DifenoxinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenhydramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
Domoic AcidMinocycline may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DoramectinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
Doxacurium chlorideMinocycline may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxepinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxylamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEMinocycline may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Investigational
DroperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved, Vet Approved
DrotebanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DyclonineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERMinocycline may increase the central nervous system depressant (CNS depressant) activities of ECGONINE METHYL ESTER.Experimental
EcopipamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzMinocycline may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EnfluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Vet Approved
EntacaponeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EstazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
EthanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl biscoumacetateMinocycline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl loflazepateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Withdrawn
EtizolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FencamfamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FentanylMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseMinocycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateMinocycline can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateMinocycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FlibanserinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FlucloxacillinThe therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Minocycline.Approved
FludiazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FluindioneMinocycline may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FlupentixolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
Fluticasone PropionateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.Approved
FluvoxamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosphenytoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit
GabapentinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
gabapentin enacarbilMinocycline may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
Gallamine TriethiodideMinocycline may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GuanfacineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit
HexobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HydrocodoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyzineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved
IloperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IronMinocycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMinocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateThe serum concentration of Minocycline can be decreased when it is combined with Iron saccharate.Approved
IsofluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsotretinoinThe risk or severity of adverse effects can be increased when Minocycline is combined with Isotretinoin.Approved
KetamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
LamotrigineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Minocycline can be decreased when it is combined with Lanthanum carbonate.Approved
LevetiracetamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobupivacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved
LevocabastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
Levomethadyl AcetateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
LevorphanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LidocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LithiumMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LoratadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LoxapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
Lu AA21004Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lu AA21004.Investigational
LurasidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateMagnesium salicylate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MecamylamineMinocycline may increase the neuromuscular blocking activities of Mecamylamine.Approved
MeclizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedetomidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MelatoninMinocycline may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved
MepivacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MesoridazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
MetaxaloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethapyrileneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
MethsuximideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethylphenobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MeticillinThe therapeutic efficacy of Meticillin can be decreased when used in combination with Minocycline.Approved
MetocurineMinocycline may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMinocycline may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MezlocillinThe therapeutic efficacy of Mezlocillin can be decreased when used in combination with Minocycline.Approved
MidazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MipomersenMinocycline may increase the hepatotoxic activities of Mipomersen.Approved
MirtazapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumMinocycline may increase the neuromuscular blocking activities of Mivacurium.Approved
MolindoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
NabiloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
NafcillinThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Minocycline.Approved
NalbuphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NeosaxitoxinMinocycline may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NitrazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
Nitrous oxideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NormethadoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
OlanzapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlopatadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumMinocycline may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrphenadrineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantMinocycline may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxacillinThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Minocycline.Approved
OxazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxetacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxetacaine.Investigational
OxprenololMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PancuroniumMinocycline may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PentazocineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PerampanelMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perampanel.Approved
PerazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerospironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenindioneMinocycline may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoxyethanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenoxymethylpenicillinThe therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
PhenprocoumonMinocycline may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Minocycline.Approved
PimozideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PipamperoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
PipecuroniumMinocycline may increase the neuromuscular blocking activities of Pipecuronium.Approved
PiperacillinThe therapeutic efficacy of Piperacillin can be decreased when used in combination with Minocycline.Approved
PipotiazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
PiritramideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PivampicillinThe therapeutic efficacy of Pivampicillin can be decreased when used in combination with Minocycline.Approved
PivmecillinamThe therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Minocycline.Approved
PizotifenMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PramocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PregabalinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PregnanoloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pregnanolone.Investigational
PrilocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
Procaine benzylpenicillinThe therapeutic efficacy of Procaine benzylpenicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
ProchlorperazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
ProparacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
ProtriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
PSD502Minocycline may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PyrantelMinocycline may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinaprilThe serum concentration of Minocycline can be decreased when it is combined with Quinapril.Approved, Investigational
RacloprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RapacuroniumMinocycline may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
RisperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RocuroniumMinocycline may increase the neuromuscular blocking activities of Rocuronium.Approved
RomifidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopivacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
S-EthylisothioureaMinocycline may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Experimental
Sage 547Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sage 547.Investigational
ScopolamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SertindoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Withdrawn
SevofluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
Sodium oxybateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
StiripentolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
Strontium ranelateThe serum concentration of Minocycline can be decreased when it is combined with Strontium ranelate.Approved
SuccinylcholineMinocycline may increase the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateSucralfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulbactamThe therapeutic efficacy of Sulbactam can be decreased when used in combination with Minocycline.Approved
SulpirideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
SultamicillinThe therapeutic efficacy of Sultamicillin can be decreased when used in combination with Minocycline.Investigational
SuvorexantMinocycline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.Approved
TasimelteonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TazobactamThe therapeutic efficacy of Tazobactam can be decreased when used in combination with Minocycline.Approved
TemazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TetrabenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrodotoxinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
ThiothixeneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiaprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Investigational
TicarcillinThe therapeutic efficacy of Ticarcillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
TiletamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TizanidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolcaponeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TopiramateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TramadolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TrazodoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Minocycline is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
TrifluoperazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TriflupromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TubocurarineMinocycline may increase the neuromuscular blocking activities of Tubocurarine.Approved
Uc1010Minocycline may increase the central nervous system depressant (CNS depressant) activities of Uc1010.Investigational
Valproic AcidMinocycline may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VecuroniumMinocycline may increase the neuromuscular blocking activities of Vecuronium.Approved
VigabatrinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VortioxetineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
WarfarinMinocycline may increase the anticoagulant activities of Warfarin.Approved
XylazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
ZaleplonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZiprasidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved
ZuclopenthixolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Calcium and iron needs increased with long term use.
  • Do not take Aluminum or magnesium antacids or supplements while on this medication.
  • Take with food.
References
Synthesis Reference

Zita Mendes, Jose Rafael Antunes, Susana Marto, William Heggie, “Crystalline Minocycline Base and Processes for its Preparation.” U.S. Patent US20100286417, issued November 11, 2010.

US20100286417
General References
  1. Gough A, Chapman S, Wagstaff K, Emery P, Elias E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996 Jan 20;312(7024):169-72. [PubMed:8563540 ]
  2. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929 ]
  3. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001 Jun 15;166(12):7527-33. [PubMed:11390507 ]
  4. Nirmalananthan N, Greensmith L: Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol. 2005 Dec;18(6):712-9. [PubMed:16280684 ]
  5. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. [PubMed:15371729 ]
  6. Link [Link]
External Links
ATC CodesA01AB23J01AA08
AHFS Codes
  • 08:12.24
PDB Entries
FDA labelDownload (3.02 MB)
MSDSDownload (73.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7469
Blood Brain Barrier-0.9783
Caco-2 permeable+0.5711
P-glycoprotein substrateSubstrate0.7366
P-glycoprotein inhibitor INon-inhibitor0.7968
P-glycoprotein inhibitor IINon-inhibitor0.7036
Renal organic cation transporterNon-inhibitor0.9536
CYP450 2C9 substrateNon-substrate0.8145
CYP450 2D6 substrateNon-substrate0.9036
CYP450 3A4 substrateSubstrate0.6805
CYP450 1A2 substrateNon-inhibitor0.9088
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9081
CYP450 3A4 inhibitorNon-inhibitor0.9058
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7561
Ames testNon AMES toxic0.8909
CarcinogenicityNon-carcinogens0.9091
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4354 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9954
hERG inhibition (predictor II)Non-inhibitor0.6783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Medicis pharmaceutical corp
  • Triax pharmaceuticals llc
  • Aurobindo pharma ltd
  • Impax laboratories inc
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Lederle laboratories div american cyanamid co
  • Orapharma inc
  • Barr laboratories inc
  • Matrix laboratories ltd
  • Sandoz inc
  • Dr reddys laboratories ltd
  • Medicis Pharmaceutical Corporation
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg
CapsuleOral50 mg
PowderOral1 mg/1
PowderOral1 mg
TabletOral75 mg/1
Capsule, coated pelletsOral75 mg/1
InjectionIntravenous100 mg/1
Kit
Capsule, coated pelletsOral100 mg/1
Capsule, coated pelletsOral50 mg/1
TabletOral100 mg/1
TabletOral50 mg/1
CapsuleOral100 mg/1
CapsuleOral50 mg/1
CapsuleOral75 mg/1
Tablet, extended releaseOral135 mg/1
Tablet, extended releaseOral45 mg/1
Tablet, extended releaseOral90 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
Tablet, film coated, extended releaseOral135 mg/1
Tablet, film coated, extended releaseOral45 mg/1
Tablet, film coated, extended releaseOral90 mg/1
Tablet, film coated, extended releaseOral105 mg/1
Tablet, film coated, extended releaseOral115 mg/1
Tablet, film coated, extended releaseOral55 mg/1
Tablet, film coated, extended releaseOral65 mg/1
Tablet, film coated, extended releaseOral80 mg/1
Capsule, extended releaseOral135 mg/1
Capsule, extended releaseOral45 mg/1
Capsule, extended releaseOral90 mg/1
Prices
Unit descriptionCostUnit
Minocin PAC 100 mg Kit Box695.5USD box
Minocin kit 100 mg combo668.17USD kit
Minocin kit 50 mg combo334.78USD kit
Minocin 100 mg vial59.64USD vial
Arestin 1 mg microsphere30.0USD each
Solodyn 135 mg 24 Hour tablet24.89USD tablet
Solodyn 45 mg 24 Hour tablet24.89USD tablet
Solodyn 65 mg 24 Hour tablet24.89USD tablet
Solodyn 90 mg 24 Hour tablet24.89USD tablet
Solodyn er 115 mg tablet23.93USD tablet
Solodyn er 135 mg tablet23.93USD tablet
Solodyn er 45 mg tablet23.93USD tablet
Solodyn er 65 mg tablet23.93USD tablet
Solodyn er 90 mg tablet23.93USD tablet
Minocycline hcl powder21.0USD g
Minocycline HCl 135 mg 24 Hour tablet19.21USD tablet
Minocycline HCl 45 mg 24 Hour tablet19.21USD tablet
Dynacin 100 mg tablet13.37USD tablet
Dynacin 75 mg tablet13.12USD tablet
Minocin 100 mg capsule12.05USD capsule
Minocin 100 mg pelletized cap11.11USD pellet
Dynacin 50 mg tablet8.76USD tablet
Dynacin 75 mg capsule7.15USD capsule
Minocycline hcl 100 mg tablet6.15USD tablet
Minocin 50 mg pelletized cap5.56USD pellet
Minocin 50 mg capsule5.24USD capsule
Minocycline hcl 75 mg tablet5.14USD tablet
Dynacin 50 mg capsule3.85USD capsule
Minocycline HCl 100 mg capsule3.53USD capsule
Minocycline hcl 50 mg tablet3.5USD tablet
Minocycline HCl 75 mg capsule2.06USD capsule
Minocycline 75 mg capsule1.98USD capsule
Minocycline HCl 50 mg capsule1.77USD capsule
Minocin 100 mg Capsule1.34USD capsule
Apo-Minocycline 100 mg Capsule1.08USD capsule
Minocycline 100 mg Capsule1.08USD capsule
Mylan-Minocycline 100 mg Capsule1.08USD capsule
Novo-Minocycline 100 mg Capsule1.08USD capsule
Pms-Minocycline 100 mg Capsule1.08USD capsule
Ratio-Minocycline 100 mg Capsule1.08USD capsule
Sandoz Minocycline 100 mg Capsule1.08USD capsule
Minocin 50 mg Capsule0.69USD capsule
Apo-Minocycline 50 mg Capsule0.56USD capsule
Minocycline 50 mg Capsule0.56USD capsule
Mylan-Minocycline 50 mg Capsule0.56USD capsule
Novo-Minocycline 50 mg Capsule0.56USD capsule
Pms-Minocycline 50 mg Capsule0.56USD capsule
Ratio-Minocycline 50 mg Capsule0.56USD capsule
Sandoz Minocycline 50 mg Capsule0.56USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1330533 No1994-07-052011-07-05Canada
US5908838 No1998-02-192018-02-19Us
US6682348 No2002-03-292022-03-29Us
US7541347 No2007-04-022027-04-02Us
US7544373 No2007-04-022027-04-02Us
US7699609 No2002-03-292022-03-29Us
US7790705 No2005-06-242025-06-24Us
US7919483 No2007-03-072027-03-07Us
US8252776 No2005-06-242025-06-24Us
US8268804 No2005-06-242025-06-24Us
US8722650 No2005-06-242025-06-24Us
US9084802 No2011-05-122031-05-12Us
US9192615 No2011-11-172031-11-17Us
US9278105 No2011-05-122031-05-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility5.2E+004 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.05SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility3.07 mg/mLALOGPS
logP-0.03ALOGPS
logP-3.3ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)-2.3ChemAxon
pKa (Strongest Basic)8.25ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area164.63 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity122.54 m3·mol-1ChemAxon
Polarizability45.9 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassTetracyclines
Sub ClassNot Available
Direct ParentTetracyclines
Alternative Parents
Substituents
  • Tetracycline
  • Tetracene
  • Naphthacene
  • Anthracene carboxylic acid or derivatives
  • Tetralin
  • Dialkylarylamine
  • Aryl ketone
  • Aralkylamine
  • Benzenoid
  • Vinylogous acid
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Polyol
  • Ketone
  • Carboxamide group
  • Enol
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Trna binding
Specific Function:
The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome.
Gene Name:
rpsI
Uniprot ID:
P0A7X3
Molecular Weight:
14856.105 Da
References
  1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. [PubMed:14723559 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Translation repressor activity, nucleic acid binding
Specific Function:
One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.With S5 and S12 plays an important role in translational accuracy; many suppressors of streptomycin-dependent mutants of protein S12 are found in this protein, some but not all of which decrease translational accuracy (ram, ribosomal ambiguity muta...
Gene Name:
rpsD
Uniprot ID:
P0A7V8
Molecular Weight:
23468.915 Da
References
  1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. [PubMed:14723559 ]
3. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
unknown
Actions
inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
modulator
General Function:
Protein domain specific binding
Specific Function:
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells.
Gene Name:
IL1B
Uniprot ID:
P01584
Molecular Weight:
30747.7 Da
References
  1. Sadowski T, Steinmeyer J: Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol. 2001 Feb;28(2):336-40. [PubMed:11246672 ]
  2. Oringer RJ, Al-Shammari KF, Aldredge WA, Iacono VJ, Eber RM, Wang HL, Berwald B, Nejat R, Giannobile WV: Effect of locally delivered minocycline microspheres on markers of bone resorption. J Periodontol. 2002 Aug;73(8):835-42. [PubMed:12211491 ]
  3. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB: A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14014-9. [PubMed:8943052 ]
  4. Steinmeyer J, Daufeldt S, Taiwo YO: Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol. 1998 Jan 1;55(1):93-100. [PubMed:9413935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. [PubMed:15371729 ]
  2. Song Y, Wei EQ, Zhang WP, Ge QF, Liu JR, Wang ML, Huang XJ, Hu X, Chen Z: Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res. 2006 Apr 26;1085(1):57-67. Epub 2006 Mar 30. [PubMed:16574083 ]
  3. Chu LS, Fang SH, Zhou Y, Yu GL, Wang ML, Zhang WP, Wei EQ: Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin. 2007 Jun;28(6):763-72. [PubMed:17506934 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.
Gene Name:
MMP9
Uniprot ID:
P14780
Molecular Weight:
78457.51 Da
References
  1. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002 Jun;125(Pt 6):1297-308. [PubMed:12023318 ]
  2. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC: Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2005 Jan;288(1):F91-7. Epub 2004 Sep 7. [PubMed:15353401 ]
  3. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, Opdenakker G, Koistinaho J: Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab. 2005 Apr;25(4):460-7. [PubMed:15674236 ]
  4. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, Lin E, Yang GY, Young WL: Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006 Sep;26(9):1157-64. Epub 2006 Jan 4. [PubMed:16395286 ]
  5. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC: Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006 Jul 17;7:56. [PubMed:16846501 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vascular endothelial growth factor receptor binding
Specific Function:
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activ...
Gene Name:
VEGFA
Uniprot ID:
P15692
Molecular Weight:
27042.205 Da
References
  1. Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002 Mar 4;86(5):768-73. [PubMed:11875741 ]
  2. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004 Aug 20;95(4):364-71. Epub 2004 Jul 15. [PubMed:15256478 ]
  3. Rocchetti R, Talevi S, Margiotta C, Calza R, Corallini A, Possati L: Antiangiogenic drugs for chemotherapy of bladder tumours. Chemotherapy. 2005 Oct;51(6):291-9. Epub 2005 Oct 13. [PubMed:16224178 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Endopeptidase activity
Specific Function:
Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis.
Gene Name:
CASP1
Uniprot ID:
P29466
Molecular Weight:
45158.215 Da
References
  1. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929 ]
  2. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM: Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001 Jun;48(6):1393-9; discussion 1399-401. [PubMed:11383749 ]
  3. Vincent JA, Mohr S: Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007 Jan;56(1):224-30. [PubMed:17192486 ]
  4. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Phospholipase a2 activator activity
Specific Function:
Involved in the activation cascade of caspases responsible for apoptosis execution. At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspa...
Gene Name:
CASP3
Uniprot ID:
P42574
Molecular Weight:
31607.58 Da
References
  1. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929 ]
  2. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM: Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002 Jul;52(1):54-61. [PubMed:12112047 ]
  3. Dommergues MA, Plaisant F, Verney C, Gressens P: Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience. 2003;121(3):619-28. [PubMed:14568022 ]
  4. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH: Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 2003 Oct;20(10):1017-27. [PubMed:14588118 ]
  5. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM, Kelly ME: An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol. 2004 Nov;66(5):1113-22. Epub 2004 Aug 10. [PubMed:15304547 ]
  6. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Metal ion binding
Specific Function:
Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Cytochrome c then transfers this electron to the cytochrome oxidase complex, the final protein carrier in the mitochondrial electron-transport chain.Plays a role in apoptosis. Suppression of the anti-apoptotic members or acti...
Gene Name:
CYCS
Uniprot ID:
P99999
Molecular Weight:
11748.69 Da
References
  1. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002 May 2;417(6884):74-8. [PubMed:11986668 ]
  2. Matsuki S, Iuchi Y, Ikeda Y, Sasagawa I, Tomita Y, Fujii J: Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline. Biochem Biophys Res Commun. 2003 Dec 19;312(3):843-9. [PubMed:14680842 ]
  3. Chu HC, Lin YL, Sytwu HK, Lin SH, Liao CL, Chao YC: Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br J Pharmacol. 2005 Jan;144(2):275-82. [PubMed:15665864 ]
  4. Heo K, Cho YJ, Cho KJ, Kim HW, Kim HJ, Shin HY, Lee BI, Kim GW: Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett. 2006 May 8;398(3):195-200. Epub 2006 Feb 15. [PubMed:16469440 ]
  5. Mansson R, Hansson MJ, Morota S, Uchino H, Ekdahl CT, Elmer E: Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis. 2007 Jan;25(1):198-205. Epub 2006 Oct 24. [PubMed:17067803 ]
  6. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:14